HUP0400350A2 - Új ciano-szubsztituált dihidropirimidin-vegyületek, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Új ciano-szubsztituált dihidropirimidin-vegyületek, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0400350A2
HUP0400350A2 HU0400350A HUP0400350A HUP0400350A2 HU P0400350 A2 HUP0400350 A2 HU P0400350A2 HU 0400350 A HU0400350 A HU 0400350A HU P0400350 A HUP0400350 A HU P0400350A HU P0400350 A2 HUP0400350 A2 HU P0400350A2
Authority
HU
Hungary
Prior art keywords
alkyl
heteroarylalkyl
cycloalkyl
heterocycloalkylalkyl
arylalkyl
Prior art date
Application number
HU0400350A
Other languages
English (en)
Inventor
Spencer David Kimball
Louis J. Lombardo
David B. Rawlins
Hai-Yun Xiao
Robert Joseph Schmidt
David Kent Williams
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0400350A2 publication Critical patent/HUP0400350A2/hu
Publication of HUP0400350A3 publication Critical patent/HUP0400350A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát az általános képletű, rákellenes hatású vegyületek- amely képletben R1 hidrogénatom, alkil- és cikloalkilcsoport; R2 ésR3 egymástól függetlenül hidrogénatom, alkil-, aril-, heteroaril-,aril-alkil-, cikloalkil-, heterocikloalkil-, cikloalkil-alkil-,heterocikloalkil-alkil- és heteroaril-alkil-csoport; vagy R2 és R3összekapcsolódhatnak karbociklusos- vagy heterociklusos gyűrűvé; R4alkil-, aril-alkil-, cikloalkil-alkil-, heteroaril-alkil-,heterocikloalkil-alkil-, amino-alkil-, ciano-, R5OC-, R5O2C ésR6R5NOC- csoport; R5 és R6 egymástól függetlenül hidrogénatom, alkil-,cikloalkil-, hidroxi-alkil-, alkenil-, alkoxi-, tioalkoxi-, alkoxi-alkil-, halogén-alkil-, aril-, heteroaril-, aril-alkil-, cikloalkil-alkil-, heteroaril-alkil- és heterocikloalkil-alkil-csoport vagy -NR5R6 együtt heterocikloalkil-csoportot alkot; Z oxigén-, kénatom és -R8N- csoport; R8 hidrogénatom, ciano-, szulfonamid-, R7O-, alkil-,cikloalkil-, aril-, aril-alkil-, heterociklusos-, heteroaril- ésheteroaril-alkil-csoport; és R6 halogénatom, alkil-, aril-alkil-,cikloalkil-alkil-, heterocikloalkil-alkil- és heteroaril-alkil-csoportés gyógyszerészetileg elfogadható sóik és ezeket tartalmazógyógyszerkészítmények képezik. Ó
HU0400350A 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds, process for producing them, their use and pharmaceutical compositions containing them HUP0400350A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29
PCT/US2002/009497 WO2002079149A2 (en) 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Publications (2)

Publication Number Publication Date
HUP0400350A2 true HUP0400350A2 (hu) 2005-01-28
HUP0400350A3 HUP0400350A3 (en) 2005-06-28

Family

ID=23071059

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400350A HUP0400350A3 (en) 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds, process for producing them, their use and pharmaceutical compositions containing them

Country Status (26)

Country Link
US (1) US6809102B2 (hu)
EP (1) EP1373221A4 (hu)
JP (1) JP2005504725A (hu)
KR (1) KR20030086327A (hu)
CN (1) CN1507435A (hu)
AR (1) AR034585A1 (hu)
BG (1) BG108180A (hu)
BR (1) BR0208405A (hu)
CA (1) CA2442482A1 (hu)
CZ (1) CZ20032645A3 (hu)
EE (1) EE200300474A (hu)
HR (1) HRP20030875A2 (hu)
HU (1) HUP0400350A3 (hu)
IL (1) IL157441A0 (hu)
IS (1) IS6967A (hu)
MX (1) MXPA03008634A (hu)
NO (1) NO20034300L (hu)
PE (1) PE20021013A1 (hu)
PL (1) PL373759A1 (hu)
RU (1) RU2003130961A (hu)
SK (1) SK11062003A3 (hu)
TW (1) TWI228416B (hu)
UY (1) UY27232A1 (hu)
WO (1) WO2002079149A2 (hu)
YU (1) YU75803A (hu)
ZA (2) ZA200306648B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP1454903B9 (en) * 2001-12-11 2011-10-05 Kyowa Hakko Kirin Co., Ltd. Thiadiazoline derivatives for treating cancer
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
MXPA05009577A (es) * 2003-03-07 2005-12-12 Astrazeneca Ab Heterociclos fundidos novedosos y sus usos.
ES2377498T3 (es) * 2003-04-18 2012-03-28 Kyowa Hakko Kirin Co., Ltd. Inhibidor de quinesina en etapa M
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005037799A1 (en) * 2003-10-16 2005-04-28 Cytokinetics, Inc. Compounds, compositions, and methods
KR20070044458A (ko) * 2004-07-22 2007-04-27 아스트라제네카 아베 암의 예방 및 치료에 유용한 융합 피리미돈
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
CA2575188A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
EP1870404A4 (en) * 2005-03-22 2010-07-14 Kyowa Hakko Kirin Co Ltd MEANS FOR THE TREATMENT OF A HEMATOPOIETIC TUMOR
KR20070113300A (ko) * 2005-03-22 2007-11-28 교와 핫꼬 고교 가부시끼가이샤 고형종양 치료제
EP1908755A4 (en) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
EE9700209A (et) 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
JP2000506904A (ja) 1996-05-16 2000-06-06 シナプティック・ファーマスーティカル・コーポレーション ジヒドロピリミジン類およびその使用
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
CA2294349A1 (en) 1997-06-18 1998-12-23 Michael A. Patane Alpha 1aadrenergic receptor antagonists
WO1999025345A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
WO1999050440A2 (en) 1998-04-01 1999-10-07 Yale University Method to identify modulators of survivin - tubulin interaction
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
ES2263501T3 (es) 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Also Published As

Publication number Publication date
CA2442482A1 (en) 2002-10-10
HUP0400350A3 (en) 2005-06-28
EP1373221A4 (en) 2004-09-29
HRP20030875A2 (en) 2004-08-31
MXPA03008634A (es) 2003-12-08
KR20030086327A (ko) 2003-11-07
IS6967A (is) 2003-09-24
EP1373221A2 (en) 2004-01-02
ZA200307320B (en) 2004-12-20
YU75803A (sh) 2006-05-25
BG108180A (en) 2004-09-30
US20030008888A1 (en) 2003-01-09
UY27232A1 (es) 2002-11-29
SK11062003A3 (sk) 2004-08-03
IL157441A0 (en) 2004-03-28
CN1507435A (zh) 2004-06-23
NO20034300L (no) 2003-11-07
BR0208405A (pt) 2004-03-30
TWI228416B (en) 2005-03-01
PE20021013A1 (es) 2002-11-10
AR034585A1 (es) 2004-03-03
EE200300474A (et) 2003-12-15
US6809102B2 (en) 2004-10-26
CZ20032645A3 (cs) 2004-06-16
JP2005504725A (ja) 2005-02-17
ZA200306648B (en) 2004-11-26
NO20034300D0 (no) 2003-09-26
WO2002079149A3 (en) 2003-02-27
WO2002079149A2 (en) 2002-10-10
RU2003130961A (ru) 2005-04-10
PL373759A1 (en) 2005-09-05

Similar Documents

Publication Publication Date Title
HUP0400350A2 (hu) Új ciano-szubsztituált dihidropirimidin-vegyületek, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0203841A2 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
HUP0402320A2 (hu) Ariloxifenil- és arilszulfanilfenil-piperazin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0302153A2 (hu) Kemokin receptor aktívitás modulátoraiként hatásos piperidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0401481A2 (hu) Kinolinszármazékok, mint neuropeptid Y antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0203316A2 (hu) Amino-triazolopiridin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ZA200505273B (en) Novel compound
HUP0203971A2 (hu) Imidazoimidazolok és -triazolok mint gyulladásellenes szerek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0300497A2 (hu) Humán foszfatidilinozit-3-kináz-delta inhibitorok és alkalmazásuk
HUP0000914A2 (hu) 3-Aril-4 (3H)-kinazolinon-származékok atropizomerjei és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
HUP0402019A2 (hu) CCR5 antagonistaként alkalmazható piperidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP0104959A2 (hu) 4-Kinolinkarboxamid-származékok, előállításuk, neurokinin-2 (NK-2) és neurokinin-3 (NK-3) receptor antagonistákként történő felhasználásuk, valamint a vegyületeket tartalmazó gyógyszerkészítmények
MY123193A (en) Novel 2-(iminomethyl)amino-phenyl derivatives,preparation,application as medicines and compositions containing same
HUP0400341A2 (hu) Ciano-szubsztituált dihidropirimidin-vegyületek és alkalmazásuk
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
HUP0402261A2 (hu) Piperidinszármazékok és alkalmazásuk kemokin receptor aktivitás modulátoraiként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402675A2 (hu) HIV integráz inhibitor hatású hidroxilaminszármazékok, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE233754T1 (de) Diphenyl-piperidin derivate
HUP0204347A2 (en) Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them and their use
HUP0400806A2 (hu) Heterokondenzált (gamma)-laktám-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
HUP0402567A2 (hu) Piperidinszármazékok és alkalmazásuk kemokin receptor (különösen CCR5) aktivitás modulátoraiként
HUP0303593A2 (hu) Biguanidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0402585A2 (hu) Új benzotiazin- benzotiadiazin-származékok, előállításuk, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees